Lena Wu

Lena Wu is a technology and biopharmaceutical advisor who has previously worked as the CEO and president of Intabio and as a strategic advisor for SCIEX. Lena has over ten years of experience in the biologics industry, during which they have gained deep insight into the needs of their customers. In their current role at Phizzle, they are using this knowledge to help the company develop a proprietary microfluidic platform that will provide real-time, rapid, and direct characterization of intact protein isoforms.

Lena Wu has a Ph.D. in Molecular Pharmacology from Stanford University School of Medicine and a BS in Biology from Stanford University. Lena is certified from Boardwise in Board Certification Program, Board Bona Fide assessment.